Teprasiran clinical trials
Also written QPI-1002 and I5NP.
How each study uses teprasiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Quark Pharmaceuticals (6)
Studies
Open first, then newest update. How each study uses teprasiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac SurgeryTerminatedPhase 3Quark PharmaceuticalsNCT03510897Written as teprasiran
- QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney TransplantCompletedPhase 3Quark PharmaceuticalsNCT02610296Written as QPI-1002
- A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac SurgeryCompletedPhase 2Quark PharmaceuticalsNCT02610283Written as QPI-1002
- I5NP for Prophylaxis of Delayed Graft Function in Kidney TransplantationCompletedPhase 1/2Quark PharmaceuticalsNCT00802347Written as I5NP
- A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular SurgeryCompletedPhase 1Quark PharmaceuticalsNCT00554359Written as I5NP (a small interfering RNA)
- A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)TerminatedPhase 1Quark PharmaceuticalsNCT00683553Written as I5NP
Codes
What other systems call teprasiran · ClinicalTrials.gg INT017432
- UNII (FDA) O03W5S19PJTEPRASIRANOne source FDA
- NCI Thesaurus C152565TeprasiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | O03W5S19PJ | TEPRASIRAN | One source FDA |
| NCI Thesaurus | C152565 | Teprasiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.